FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200224382> ?p ?o ?g. }

• W3200224382 endingPage "106707" @default.
• W3200224382 startingPage "106707" @default.
• W3200224382 abstract "Despite advances in immunotherapies, the prognosis for adults with Philadelphia chromosome-negative, newly diagnosed (ND) or relapsed/refractory (R/R) acute lymphoblastic leukemia/acute biphenotypic leukemia (ALL/ABL) remains poor. The benzamide derivative entinostat inhibits histone deacetylase and induces histone hyperacetylation. The purine nucleoside analogue clofarabine is FDA-approved for R/R ALL in children 1−21 years of age. Low doses of clofarabine have been reported to induce DNA hypomethylation. We conducted a phase 1 study of low dose clofarabine with escalating doses of entinostat in adults with ND or R/R ALL/ABL. Adults ≥60 years with ND ALL/ABL or ≥21 years with R/R ALL/ABL received repeated cycles every 3 weeks of entinostat (4 mg, 6 mg or 8 mg orally days 1 and 8) and clofarabine (10 mg/m2/day IV for 5 days, days 3–7) (Arm A). Adults aged 40–59 years with ND ALL/ABL or age ≥21 years in first relapse received entinostat and clofarabine prior to traditional chemotherapy on day 11 (Arm B). Changes in DNA damage, global protein lysine acetylation, myeloid-derived suppressor cells and monocytes were measured in PBMCs before and during therapy. Twenty-eight patients were treated at three entinostat dose levels with the maximum administered dose being entinostat 8 mg. The regimen was well tolerated with infectious and metabolic derangements more common in the older population versus the younger cohort. There was no severe hyperglycemia and no peripheral neuropathy in this small study. There were 2 deaths (1 sepsis, 1 intracranial bleed). Overall response rate was 32 %; it was 50 % for ND ALL/ABL. Entinostat increased global protein acetylation and inhibited immunosuppressive monocyte subpopulations, while clofarabine induced DNA damage in all cell subsets examined. Entinostat plus clofarabine appears to be tolerable and active in older adults with ND ALL/ABL, but less active in R/R patients. Further evaluation of this regimen in ND ALL/ABL appears warranted." @default.
• W3200224382 created "2021-09-27" @default.
• W3200224382 creator A5008654579 @default.
• W3200224382 creator A5012395020 @default.
• W3200224382 creator A5012591920 @default.
• W3200224382 creator A5016810759 @default.
• W3200224382 creator A5017559837 @default.
• W3200224382 creator A5021095127 @default.
• W3200224382 creator A5035609080 @default.
• W3200224382 creator A5037169725 @default.
• W3200224382 creator A5040289016 @default.
• W3200224382 creator A5040758762 @default.
• W3200224382 creator A5045709974 @default.
• W3200224382 creator A5046042179 @default.
• W3200224382 creator A5046719320 @default.
• W3200224382 creator A5047654809 @default.
• W3200224382 creator A5049910941 @default.
• W3200224382 creator A5052920087 @default.
• W3200224382 creator A5059147004 @default.
• W3200224382 creator A5074766331 @default.
• W3200224382 creator A5082846946 @default.
• W3200224382 creator A5089694123 @default.
• W3200224382 date "2021-11-01" @default.
• W3200224382 modified "2023-09-30" @default.
• W3200224382 title "Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia" @default.
• W3200224382 cites W1827980340 @default.
• W3200224382 cites W182888219 @default.
• W3200224382 cites W1899314386 @default.
• W3200224382 cites W1992740422 @default.
• W3200224382 cites W1993462593 @default.
• W3200224382 cites W1993510744 @default.
• W3200224382 cites W2018172208 @default.
• W3200224382 cites W2042138663 @default.
• W3200224382 cites W2053903261 @default.
• W3200224382 cites W2064971912 @default.
• W3200224382 cites W2069771596 @default.
• W3200224382 cites W2082739830 @default.
• W3200224382 cites W2092617134 @default.
• W3200224382 cites W2093264973 @default.
• W3200224382 cites W2098536205 @default.
• W3200224382 cites W2102685625 @default.
• W3200224382 cites W2103708119 @default.
• W3200224382 cites W2107925822 @default.
• W3200224382 cites W2123900004 @default.
• W3200224382 cites W2128491464 @default.
• W3200224382 cites W2139674976 @default.
• W3200224382 cites W2140723571 @default.
• W3200224382 cites W2145822190 @default.
• W3200224382 cites W2159453510 @default.
• W3200224382 cites W2159507916 @default.
• W3200224382 cites W2163962374 @default.
• W3200224382 cites W2167118090 @default.
• W3200224382 cites W2346378690 @default.
• W3200224382 cites W2419639370 @default.
• W3200224382 cites W2514433639 @default.
• W3200224382 cites W2521076777 @default.
• W3200224382 cites W2591709377 @default.
• W3200224382 cites W2736006101 @default.
• W3200224382 cites W2753757677 @default.
• W3200224382 cites W2768556518 @default.
• W3200224382 cites W2913459787 @default.
• W3200224382 cites W2989489048 @default.
• W3200224382 cites W3127051356 @default.
• W3200224382 cites W2031450750 @default.
• W3200224382 doi "https://doi.org/10.1016/j.leukres.2021.106707" @default.
• W3200224382 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34563945" @default.
• W3200224382 hasPublicationYear "2021" @default.
• W3200224382 type Work @default.
• W3200224382 sameAs 3200224382 @default.
• W3200224382 citedByCount "5" @default.
• W3200224382 countsByYear W32002243822022 @default.
• W3200224382 countsByYear W32002243822023 @default.
• W3200224382 crossrefType "journal-article" @default.
• W3200224382 hasAuthorship W3200224382A5008654579 @default.
• W3200224382 hasAuthorship W3200224382A5012395020 @default.
• W3200224382 hasAuthorship W3200224382A5012591920 @default.
• W3200224382 hasAuthorship W3200224382A5016810759 @default.
• W3200224382 hasAuthorship W3200224382A5017559837 @default.
• W3200224382 hasAuthorship W3200224382A5021095127 @default.
• W3200224382 hasAuthorship W3200224382A5035609080 @default.
• W3200224382 hasAuthorship W3200224382A5037169725 @default.
• W3200224382 hasAuthorship W3200224382A5040289016 @default.
• W3200224382 hasAuthorship W3200224382A5040758762 @default.
• W3200224382 hasAuthorship W3200224382A5045709974 @default.
• W3200224382 hasAuthorship W3200224382A5046042179 @default.
• W3200224382 hasAuthorship W3200224382A5046719320 @default.
• W3200224382 hasAuthorship W3200224382A5047654809 @default.
• W3200224382 hasAuthorship W3200224382A5049910941 @default.
• W3200224382 hasAuthorship W3200224382A5052920087 @default.
• W3200224382 hasAuthorship W3200224382A5059147004 @default.
• W3200224382 hasAuthorship W3200224382A5074766331 @default.
• W3200224382 hasAuthorship W3200224382A5082846946 @default.
• W3200224382 hasAuthorship W3200224382A5089694123 @default.
• W3200224382 hasConcept C126322002 @default.
• W3200224382 hasConcept C143998085 @default.
• W3200224382 hasConcept C2777198975 @default.
• W3200224382 hasConcept C2778041864 @default.
• W3200224382 hasConcept C2778461978 @default.

• next